Company intelligence / Profile preview
Kamari Pharma
Ness Ziona, Central District, Israelkamaripharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Kamari Pharma develops first-in-class and best-in-class small molecule inhibitors of the TRPV3 ion channel for rare and severe genetic skin diseases. Their lead programs are in clinical development targeting conditions such as Keratoderma, Ichthyosis, Olmsted Syndrome, Lichen Simplex Chronicus, and severe chronic itch. The company’s approach aims to repair molecular damage in these disorders by modulating skin homeostasis through TRPV3 inhibition. Recent data were presented at the 81st Annual Meeting of the Society for Investigative Dermatology in May 2024.
- Therapeutic areas
- Dermatology
- Modalities
- Small molecules (TRPV3 inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kamari Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kamari Pharma.